Try as we might, we can’t cover all the biotech news out there! Here’s a roundup of news that didn’t make the cut this week.
- Boehringer Ingelheim committed €250M to Danish CRO Gubra in a diabetes deal
- Sanofi got a slight nod from the FDA for its a biosimilar of Humalog, Eli Lilly’s best-selling insulin
- Anergis scored a marginal win — 7% improvement — in a Phase IIb designed to test the efficacy of its allergy immunotherapy
- Santhera’s repurposed Duchenne muscular dystrophy drug, Raxone, got hit with a negative CHMP opinion questioning its efficacy
- AB Science also suffered a slap from CHMP: the French biotech had requested the reassessment of masitinib in indolent systemic mastocytosis, but the committee was not convinced of a favorable risk-benefit ratio
- Moderna and its partner, AstraZeneca, have let more light in to show off a newly reorganized R&D structure
- There’s a new biotech on the Leiden block: TM3 has debuted with a Nature publication as a biotech developing metabolite replacement therapies
- Finland-based BC Platforms joined forces with Microsoft Genomics to launch a platform to integrate genomic and clinical data
- Inotrem has a new lead compound in septic shock that just turned up positive preclinical results
Images via nattanan726, kunanon, hkhtt hj, Seregraff / shutterstock.com
